Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Research in Cardiology
Literature
1.
Cannon CP, Bhatt DL, Oldgren J et al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513–1524CrossRef
2.
Gibson CM, Mehran R, Bode C et al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423–2434CrossRef
3.
Dewilde WJ, Oirbans T, Verheugt FW et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107–1115CrossRef
4.
Lopes RD, Heizer G, Aronson R et al (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509–1524CrossRef
5.
Cavallari I, Patti G (2018) Meta-analysis comparing the safety and efficacy of dual versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol 121:718–724CrossRef
6.
Lou B, Liang X, Wu Y et al (2018) Meta-analysis comparing dual versus single antiplatelet therapy in combination with antithrombotic therapy in patients with atrial fibrillation who underwent percutaneous coronary intervention with stent implantation. Am J Cardiol 122:604–611CrossRef
7.
Golwala HB, Cannon CP, Steg PG et al (2018) Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 39:1726–1735CrossRef
8.
Duerschmied D, Brachmann J, Darius H et al (2018) Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials? Clin Res Cardiol 107:533–538CrossRef
9.
Lee SY, Hong MK, Shin DH et al (2017) Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. Clin Res Cardiol 106:165–173CrossRef
10.
Vranckx P, Valgimigli M, Juni P et al (2018) Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392:940–949CrossRef
Metadata
Title
Antithrombotic therapy in atrial fibrillation: stop triple therapy and start optimizing dual therapy?
Authors
Bernhard Wernly
Michael Lichtenauer
David Erlinge
Christian Jung
Publication date
01-01-2020
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 1/2020
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-019-01496-w

Other articles of this Issue 1/2020

Clinical Research in Cardiology 1/2020 Go to the issue

Original Paper

Temporal trends in management and outcome of pulmonary embolism: a single-centre experience

Original Paper

Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices

Original Paper

Right atrial–right ventricular coupling in heart failure with preserved ejection fraction

Critical Perspective

Interdisciplinary consensus on indications for transfemoral transcatheter aortic valve implantation (TF-TAVI)

Letter to the Editors

Sex differences in optimal atrioventricular delay in patients receiving cardiac resynchronization therapy

Original Paper

Real-world clinical experience with the percutaneous extracorporeal life support system: Results from the German Lifebridge® Registry

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits